The program is the latest strategic move by pharmaceutical companies to tap into the market of uninsured patients and cash-paying customers, bypassing established drug distribution networks. #selfpay #privatepay #uninsured #pharmaceuticals.

Sino Biopharmaceuticals will pay up to $951 million to acquire LaNova Medicines, a company that previously licensed drug candidates to Merck and AstraZeneca. #acquisition #pharmaceuticals #biotech.

A breakthrough for cystic fibrosis patients: NHS England has agreed to fund Vertex's new treatment. Meanwhile, Merck is making strides in HIV prevention, launching two late-stage trials for its once-monthly PrEP pill. #cysticfibrosis #HIV #drugtrials.

Baxdrostat, now part of AstraZeneca's portfolio. providing effective blood pressure control for patients whose hypertension is either not adequately managed or resistant to existing medications. #bloodpressure #drugdevelopment #pharmanews.

The company expressed its surprise at the decision, which came after several cell and gene therapy officials were removed from the agency during the review of deramiocel. #cardiomyopathy #celltherapy #genetherapy #pharmanews.

Despite exceeding Wall Street's expectations for preliminary quarterly sales, Vykat's stock price declined, fueled by investor uncertainty regarding the company's potential sale. #stockprice #pharmasales #pharmamergers.

A gradual increase in Kisunla dosage mitigates the risk of brain swelling, a complication that has tempered enthusiasm for Lilly's amyloid-clearing drug among physicians. #alzheimers #drugtrial #pharmanews.

The company anticipated the drug would generate billions of dollars, capitalizing on the significant market for women's health products. #endometriosis #womenshealth #drugtrial #pharmanews.

IGM, another biotech company grappling with financial difficulties, has been acquired by Concentra. This deal comes as Regeneron anticipates a boost to its oncology business from its bispecific antibody pipeline. #myeloma #antibodytherapy.

Patients undergoing treatment for complex cancers will benefit from the agency's changes, which eliminate difficult requirements for their medications and loosen restrictions on their post-treatment mobility. #cancertreatment #cart3 #cancer #biotech.

The biotech company has forged a new partnership with Gilead to develop molecular glue degraders. This follows a shift in focus from their existing collaboration with Sanofi, which is now concentrating on a different drug candidate. #biotechnology.

Nuvalent's research points towards a potentially groundbreaking treatment for ROS1-positive lung cancer, though the crowded market presents a significant challenge to achieving strong sales. #lungcancer #lungcancertreatment #drugtrial.

Positive Phase 2 results for the company's flu prevention drug doubled its share value, positioning it as a potential vaccine alternative. #flu #fluseason #antivirals #drugtrial.

Prothena announced a significant restructuring, slashing its workforce by 63% and exploring potential strategic alternatives. #restructuring #obesitytreatment #clinicaltrials.

The FDA, under Commissioner Martin Makary, is piloting a voucher program that could expedite drug reviews to one or two months. This fast-track approval process is contingent on the drug meeting specific requirements. #fdaapproval #fdafasttrack #fda.

The deal concerns a cardiovascular drug with transformative potential, according to Lilly. This agreement follows a period of declining share value for Verve, fueled by market uncertainty about the drug's necessity. #cardiovasculardisease #geneediting.

In a $1.25 billion acquisition, BioNTech bolsters its cancer drug pipeline and eliminates potential royalty payments to CureVac, resolving ongoing patent disputes. #cancerdrugs #mrna #pharmanews.

With backing from the venture arms of pharmaceutical giants Sanofi, Roche, and Novartis, this company is developing a cutting-edge gene therapy platform. #genetherapy.

This offer is the latest in a series of acquisitions by Concentra, a Tang Capital Partners-backed investment vehicle, focused on purchasing and liquidating underperforming biotechnology companies. #biotech #pharmanews #biotechcompanies.

Negative news rocked the biotech sector. Otsuka's late-stage IgA nephropathy results prompted a sell-off of Vera Therapeutics stock. Meanwhile, investors were wary of Regenxbio's Duchenne muscular dystrophy data. #pharmanews.